Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation

Soo Mee Bang; Jong Seok Lee; Jeong Yeal Ahn; Jae Hoon Lee; Myung Soo Hyun; Bong Seog Kim; Moo Rim Park; Hyun Sook Chi; Ho Young Kim; Hyo Jung Kim; Moon Hee Lee; Hwak Kim; Jong Ho Won; Hwi Joong Yoon; Do Yeun Oh; Eun Mi Nam; Sung Hwa Baels; Byoung Kook Kim

doi:10.1160/TH08-06-0396

Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation

Soo Mee Bang, Jong Seok Lee, Jeong Yeal Ahn, Jae Hoon Lee, Myung Soo Hyun, Bong Seog Kim, Moo Rim Park, Hyun Sook Chi, Ho Young Kim, Hyo Jung Kim, Moon Hee Lee, Hwak Kim, Jong Ho Won, Hwi Joong Yoon, Do Yeun Oh, Eun Mi Nam, Sung Hwa Baels, Byoung Kook Kim

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Evaluation of the Janus kinase 2 (JAK2) V617F mutation has been widely used for the diagnosis of myeloproliferative neoplasms (MPN). However, its prognostic relevance to clinical outcome is not completely understood.We investigated the association of JAK2V617F with vascular events in Korean patients with myeloproliferative neoplasms (MPN).We studied 283 patients from 15 centers, who were diagnosed with MPN.The JAK2V617F status was evaluated by allele-specific polymerase chain reaction (PCR) and sequencing. The patients' diagnoses were essential thrombocythemia (ET n= 146), polycythemia vera (PV n=120), primary myelofibrosis (n= 12), and unclassifiable MPN (MPNu n=5). JAK2V617F was detected in 89 (61%) patients with ET, 103 (86%) with PV, four (33%) with myelofibrosis, and four (80%) with MPNu.A higher number of leukocytes, haemoglobin levels and BM cellularity as well as an older age, lower platelet counts, and diagnosis of PV were significantly correlated with JAK2 V617F. Eighty-three and 43 episodes of thrombosis and bleeding occurred in 100 patients each before and after the diagnosis.Vascular events more frequently occurred in 37% of patients with JAK2 V617F than in 29% of those without the mutation (p=0.045). Among 175 patients whose samples were available for sequencing, 28 patients with homozygous JAK2 V617F had vascular events more frequently (57%) than those who were heterozygotes (39%) or had the wild type (27%) (p=0.03).The multivariate analysis showed that a JAK2 homozygous mutation, hypercholesterolemia and older age were independent risk factors for a vascular event. The results of this study showed that Korean patients with MPN had a similar JAK2 mutation rate and frequency of vascular events when compared to Western patients.The presence of V617F was significantly related to vascular events.Therefore, initial evaluation for the JAK2 mutation and careful monitoring for vascular events should be performed in MPN patients.

Original language	English
Pages (from-to)	547-551
Number of pages	5
Journal	Thrombosis and Haemostasis
Volume	101
Issue number	3
DOIs	https://doi.org/10.1160/TH08-06-0396
State	Published - Mar 2009

Keywords

Bleeding
Janus kinase 2
Myeloproliferative disorders
Thrombosis

Access to Document

10.1160/TH08-06-0396

Cite this

Bang, S. M., Lee, J. S., Ahn, J. Y., Lee, J. H., Hyun, M. S., Kim, B. S., Park, M. R., Chi, H. S., Kim, H. Y., Kim, H. J., Lee, M. H., Kim, H., Won, J. H., Yoon, H. J., Oh, D. Y., Nam, E. M., Baels, S. H., & Kim, B. K. (2009). Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation. Thrombosis and Haemostasis, 101(3), 547-551. https://doi.org/10.1160/TH08-06-0396

@article{a2b3bdba9868476fbe3d4e4f148041e9,

title = "Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation",

abstract = "Evaluation of the Janus kinase 2 (JAK2) V617F mutation has been widely used for the diagnosis of myeloproliferative neoplasms (MPN). However, its prognostic relevance to clinical outcome is not completely understood.We investigated the association of JAK2V617F with vascular events in Korean patients with myeloproliferative neoplasms (MPN).We studied 283 patients from 15 centers, who were diagnosed with MPN.The JAK2V617F status was evaluated by allele-specific polymerase chain reaction (PCR) and sequencing. The patients' diagnoses were essential thrombocythemia (ET n= 146), polycythemia vera (PV n=120), primary myelofibrosis (n= 12), and unclassifiable MPN (MPNu n=5). JAK2V617F was detected in 89 (61%) patients with ET, 103 (86%) with PV, four (33%) with myelofibrosis, and four (80%) with MPNu.A higher number of leukocytes, haemoglobin levels and BM cellularity as well as an older age, lower platelet counts, and diagnosis of PV were significantly correlated with JAK2 V617F. Eighty-three and 43 episodes of thrombosis and bleeding occurred in 100 patients each before and after the diagnosis.Vascular events more frequently occurred in 37% of patients with JAK2 V617F than in 29% of those without the mutation (p=0.045). Among 175 patients whose samples were available for sequencing, 28 patients with homozygous JAK2 V617F had vascular events more frequently (57%) than those who were heterozygotes (39%) or had the wild type (27%) (p=0.03).The multivariate analysis showed that a JAK2 homozygous mutation, hypercholesterolemia and older age were independent risk factors for a vascular event. The results of this study showed that Korean patients with MPN had a similar JAK2 mutation rate and frequency of vascular events when compared to Western patients.The presence of V617F was significantly related to vascular events.Therefore, initial evaluation for the JAK2 mutation and careful monitoring for vascular events should be performed in MPN patients.",

keywords = "Bleeding, Janus kinase 2, Myeloproliferative disorders, Thrombosis",

author = "Bang, {Soo Mee} and Lee, {Jong Seok} and Ahn, {Jeong Yeal} and Lee, {Jae Hoon} and Hyun, {Myung Soo} and Kim, {Bong Seog} and Park, {Moo Rim} and Chi, {Hyun Sook} and Kim, {Ho Young} and Kim, {Hyo Jung} and Lee, {Moon Hee} and Hwak Kim and Won, {Jong Ho} and Yoon, {Hwi Joong} and Oh, {Do Yeun} and Nam, {Eun Mi} and Baels, {Sung Hwa} and Kim, {Byoung Kook}",

year = "2009",

month = mar,

doi = "10.1160/TH08-06-0396",

language = "English",

volume = "101",

pages = "547--551",

journal = "Thrombosis and Haemostasis",

issn = "0340-6245",

publisher = "Georg Thieme Verlag",

number = "3",

}

Bang, SM, Lee, JS, Ahn, JY, Lee, JH, Hyun, MS, Kim, BS, Park, MR, Chi, HS, Kim, HY, Kim, HJ, Lee, MH, Kim, H, Won, JH, Yoon, HJ, Oh, DY, Nam, EM, Baels, SH & Kim, BK 2009, 'Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation', Thrombosis and Haemostasis, vol. 101, no. 3, pp. 547-551. https://doi.org/10.1160/TH08-06-0396

TY - JOUR

T1 - Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation

AU - Bang, Soo Mee

AU - Lee, Jong Seok

AU - Ahn, Jeong Yeal

AU - Lee, Jae Hoon

AU - Hyun, Myung Soo

AU - Kim, Bong Seog

AU - Park, Moo Rim

AU - Chi, Hyun Sook

AU - Kim, Ho Young

AU - Kim, Hyo Jung

AU - Lee, Moon Hee

AU - Kim, Hwak

AU - Won, Jong Ho

AU - Yoon, Hwi Joong

AU - Oh, Do Yeun

AU - Nam, Eun Mi

AU - Baels, Sung Hwa

AU - Kim, Byoung Kook

PY - 2009/3

Y1 - 2009/3

N2 - Evaluation of the Janus kinase 2 (JAK2) V617F mutation has been widely used for the diagnosis of myeloproliferative neoplasms (MPN). However, its prognostic relevance to clinical outcome is not completely understood.We investigated the association of JAK2V617F with vascular events in Korean patients with myeloproliferative neoplasms (MPN).We studied 283 patients from 15 centers, who were diagnosed with MPN.The JAK2V617F status was evaluated by allele-specific polymerase chain reaction (PCR) and sequencing. The patients' diagnoses were essential thrombocythemia (ET n= 146), polycythemia vera (PV n=120), primary myelofibrosis (n= 12), and unclassifiable MPN (MPNu n=5). JAK2V617F was detected in 89 (61%) patients with ET, 103 (86%) with PV, four (33%) with myelofibrosis, and four (80%) with MPNu.A higher number of leukocytes, haemoglobin levels and BM cellularity as well as an older age, lower platelet counts, and diagnosis of PV were significantly correlated with JAK2 V617F. Eighty-three and 43 episodes of thrombosis and bleeding occurred in 100 patients each before and after the diagnosis.Vascular events more frequently occurred in 37% of patients with JAK2 V617F than in 29% of those without the mutation (p=0.045). Among 175 patients whose samples were available for sequencing, 28 patients with homozygous JAK2 V617F had vascular events more frequently (57%) than those who were heterozygotes (39%) or had the wild type (27%) (p=0.03).The multivariate analysis showed that a JAK2 homozygous mutation, hypercholesterolemia and older age were independent risk factors for a vascular event. The results of this study showed that Korean patients with MPN had a similar JAK2 mutation rate and frequency of vascular events when compared to Western patients.The presence of V617F was significantly related to vascular events.Therefore, initial evaluation for the JAK2 mutation and careful monitoring for vascular events should be performed in MPN patients.

AB - Evaluation of the Janus kinase 2 (JAK2) V617F mutation has been widely used for the diagnosis of myeloproliferative neoplasms (MPN). However, its prognostic relevance to clinical outcome is not completely understood.We investigated the association of JAK2V617F with vascular events in Korean patients with myeloproliferative neoplasms (MPN).We studied 283 patients from 15 centers, who were diagnosed with MPN.The JAK2V617F status was evaluated by allele-specific polymerase chain reaction (PCR) and sequencing. The patients' diagnoses were essential thrombocythemia (ET n= 146), polycythemia vera (PV n=120), primary myelofibrosis (n= 12), and unclassifiable MPN (MPNu n=5). JAK2V617F was detected in 89 (61%) patients with ET, 103 (86%) with PV, four (33%) with myelofibrosis, and four (80%) with MPNu.A higher number of leukocytes, haemoglobin levels and BM cellularity as well as an older age, lower platelet counts, and diagnosis of PV were significantly correlated with JAK2 V617F. Eighty-three and 43 episodes of thrombosis and bleeding occurred in 100 patients each before and after the diagnosis.Vascular events more frequently occurred in 37% of patients with JAK2 V617F than in 29% of those without the mutation (p=0.045). Among 175 patients whose samples were available for sequencing, 28 patients with homozygous JAK2 V617F had vascular events more frequently (57%) than those who were heterozygotes (39%) or had the wild type (27%) (p=0.03).The multivariate analysis showed that a JAK2 homozygous mutation, hypercholesterolemia and older age were independent risk factors for a vascular event. The results of this study showed that Korean patients with MPN had a similar JAK2 mutation rate and frequency of vascular events when compared to Western patients.The presence of V617F was significantly related to vascular events.Therefore, initial evaluation for the JAK2 mutation and careful monitoring for vascular events should be performed in MPN patients.

KW - Bleeding

KW - Janus kinase 2

KW - Myeloproliferative disorders

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=62549140121&partnerID=8YFLogxK

U2 - 10.1160/TH08-06-0396

DO - 10.1160/TH08-06-0396

M3 - Article

C2 - 19277418

AN - SCOPUS:62549140121

SN - 0340-6245

VL - 101

SP - 547

EP - 551

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

IS - 3

ER -

Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation

Abstract

Keywords

Access to Document

Fingerprint

Cite this